
Loading, please wait...

Loading, please wait...

Deoxynivalenol (DON), frequently referred to as vomitoxin, is a prevalent trichothecene mycotoxin that contaminates cereal-based foods worldwide. This toxin poses a significant threat to intestinal health in both humans and livestock by disrupting the epithelial barrier and triggering inflammation. Recent research has identified that glucuronolactone intestinal injury protection offers a promising nutritional strategy to mitigate these harmful effects.
Glucuronolactone (GLU) effectively alleviates the damage caused by DON through a multifaceted mechanism that centers on the intestinal mucus barrier. Specifically, GLU promotes mucin sulfation, a biochemical process that strengthens the mucus layer and enhances its protective capacity. Consequently, the fortified barrier prevents the translocation of toxins and pathogens into the deeper layers of the intestinal tissue.
The study reveals that GLU operates through two distinct pathways: one dependent on the gut microbiota and one independent of it. In the microbiota-dependent pathway, GLU increases the abundance of the probiotic Lactobacillus amylovorus. This bacterium produces indole-3-acetic acid (IAA), which acts as a ligand for the aryl hydrocarbon receptor (AHR). Furthermore, GLU can directly activate AHR in a microbiota-independent manner. This dual activation is crucial for maintaining intestinal homeostasis under toxic stress.
Once activated, AHR transcriptionally up-regulates the expression of the sulfotransferase GAL3ST3. This enzyme is the primary driver behind the enhanced mucin sulfation observed in the study. Moreover, the increased sulfation level directly correlates with reduced inflammation and improved tissue recovery. Therefore, targeting the AHR-GAL3ST3 axis through nutritional interventions like GLU could represent a breakthrough in managing environmental toxin exposure.
Mucin sulfation is essential for protecting the gut lining from enzymatic degradation and toxic insults. By increasing the negative charge of the mucus, it creates a more resilient shield against common dietary toxins like deoxynivalenol.
Glucuronolactone promotes the growth of beneficial bacteria such as Lactobacillus amylovorus. These probiotics produce metabolites like indole-3-acetic acid, which then signal the host's immune system to strengthen the intestinal barrier.
While the primary study used piglet models, the conserved nature of the AHR pathway and mucin regulation suggests that GLU may serve as an effective nutritional supplement for humans exposed to mycotoxin-contaminated grains.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the guidance of a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Cui C et al. Glucuronolactone Promotes Mucin Sulfation to Alleviate Deoxynivalenol-Induced Intestinal Injury via Microbiota-Dependent and -Independent AHR Activation. Adv Sci (Weinh). 2026 Feb 23. doi: 10.1002/advs.202522912. PMID: 41725587.
Wan ML et al. Deoxynivalenol modulated mucin expression and proinflammatory cytokine production, affecting susceptibility to enteroinvasive Escherichia coli infection in intestinal epithelial cells. PMC. 2025.
Ji T et al. Indole-3-Acetic Acid Alters Intestinal Microbiota and Alleviates Ankylosing Spondylitis in Mice. Front Immunol. 2025.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research identifies glucuronolactone as a key protector of the intestinal barrier against DON mycotoxins through AHR-mediated mucin sulfation....
5 months ago

A cross-sectional analysis from the Electronic Framingham Heart Study reveals that a higher daily heart rate per step ratio is associated with lower composite cognitive scores in older adults, highlighting smartwatch metrics as valuable tools for detecting subclinical cardiovascular factors linked to brain health.
Today

A multicenter study identifies a three-metabolite gut microbiota panel (3-hydroxydecanoic acid, γ-Glu-Leu, and propionic acid) for early risk stratification of gestational diabetes mellitus in the first trimester, offering superior predictive accuracy over standard clinical risk factors before 24 weeks.
Today

A comprehensive 50-year study reveals an 82% decrease in overall US stroke mortality from 1970 to 2023. While ischemic and hemorrhagic stroke deaths dropped significantly due to clinical and public health advances, racial disparities persist, with Black adults continuing to experience the highest mortality rates.
Today

A cadaveric study demonstrates that the Chinese knotting technique significantly improves maximum load capacity and reduces graft relaxation length in posterior cruciate ligament reconstruction, offering superior biomechanical stability compared to conventional reconstruction methods without altering stiffness.
Today

Discover clinical pitfalls in diagnosing SGLT2 inhibitor ketoacidosis in the ICU. Learn how cardiac surgery and GLP-1 agonist interactions trigger euglycemic DKA and explore management strategies.
Today